TCF3 Induces DNMT1 Expression to Regulate Wnt Signaling Pathway in Glioma

Zeng, Wenjuan; Jiang, Haixiao; Wang, Ying; Wang, Cunzu; Yu, Bo

doi:10.1007/s12640-022-00510-w

Cited by 4 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zeng et al. ( 28 ) reported that DNMT1 is highly expressed in gliomas to promote tumor development and block tumor apoptosis in vivo , which is related to the WNT pathway. NSUN2 is highly expressed in U87 and regulates the migration ability of tumor cells.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comprehensive analysis of m6A/m5C/m1A-related gene expression, immune infiltration, and sensitivity of antineoplastic drugs in glioma

Zhao

Wen-hu²,

Yang³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

This research aims to develop a prognostic glioma marker based on m6A/m5C/m1A genes and investigate the potential role in the tumor immune microenvironment. Data for patients with glioma were downloaded from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA). The expression of genes related to m6A/m5C/m1A was compared for normal and glioma groups. Gene Ontology and Kyoto Encyclopedia of Genes and Gene enrichment analysis of differentially expressed genes were conducted. Consistent clustering analysis was performed to obtain glioma subtypes and complete the survival analysis and immune analysis. Based on TCGA, Lasso regression analysis was used to obtain a prognostic model, and the CGGA database was used to validate the model. The model-based risk scores and the hub genes with the immune microenvironment, clinical features, and antitumor drug susceptibility were investigated. The clinical glioma tissues were collected to verify the expression of hub genes via immunohistochemistry. Twenty genes were differentially expressed, Consensus cluster analysis identified two molecular clusters. Overall survival was significantly higher in cluster 2 than in cluster 1. Immunological analysis revealed statistically significant differences in 26 immune cells and 17 immune functions between the two clusters. Enrichment analysis detected multiple meaningful pathways. We constructed a prognostic model that consists of WTAP, TRMT6, DNMT1, and DNMT3B. The high-risk and low-risk groups affected the survival prognosis and immune infiltration, which were related to grade, gender, age, and survival status. The prognostic value of the model was validated using another independent cohort CGGA. Clinical correlation and immune analysis revealed that four hub genes were associated with tumor grade, immune cells, and antitumor drug sensitivity, and WTAP was significantly associated with microsatellite instability(MSI). Immunohistochemistry confirmed the high expression of WTAP, DNMT1, and DNMT3B in tumor tissue, but the low expression of TRMT6. This study established a strong prognostic marker based on m6A/m5C/m1A methylation regulators, which can accurately predict the prognosis of patients with gliomas. m6A/m5C/m1A modification mode plays an important role in the tumor microenvironment, can provide valuable information for anti-tumor immunotherapy, and have a profound impact on the clinical characteristics.

show abstract

Section: Discussionmentioning

confidence: 99%

“…WTAP can also encourage glioma cell invasion and migration ( 36 , 37 ). DNMT1 plays a role in glioma growth, apoptosis, and migration ( 28 ). Glioma growth is slowed in vitro and in vivo experiments when a DNMT1 inhibitor is given ( 36 ).…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of m6A/m5C/m1A-related gene expression, immune infiltration, and sensitivity of antineoplastic drugs in glioma

Zhao

Wen-hu²,

Yang³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…However, their effectiveness remains constrained [3,4] . Despite multiple treatment approaches, the average overall survival in patients with glioblastoma is 14.6 months [5] . Consequently, investigating the molecular biological attributes of glioma, identifying biomarkers capable of predicting prognosis and immunotherapy response, and discovering new treatment approaches are crucial.…”

Section: Introductionmentioning

confidence: 99%

Targeting inhibition of prognosis-related nicotinamide metabolism genes, including poly (ADP-ribose) polymerase 9 (PARP-9) attenuates glioma progression

Zeng,

Jiang,

Sun

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Nicotinamide (NAM) metabolism plays a significant role in glioma development. This study aimed to investigate the correlation between NAM metabolic genes and prognosis, immune microenvironment, and tumor progression in glioma. Methods We analyzed the expression and prognostic significance of NAM-metabolism-related genes in patients with glioma to develop a new NAM metabolism-related signature (NMRS) and nomograms using data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases and compared the differences in gene set enrichment analysis (GSEA), protein-protein interaction networks, competing endogenous RNA (ceRNA) regulatory network, prognosis, mutation load, and immune landscape between different groups. Additionally, we employed Western blotting, cell proliferation and apoptosis analysis, Semi-quantitative Reverse Transcription-Polymerase Chain Reaction(SqRT-PCR), and a xenograft model in nude mice to investigate the role of PARP9 in tumor progression. Results Our study identified eight genes, including NT5C1A, NNMT, CDKN1A, PTGS2, PNP, PARP10, PARP14, and PARP9, that exhibited a significant correlation with glioma prognosis and could act as an independent indicator. Risk stratification was conducted based on the NMRS, and the low-risk group exhibited more favorable clinical results. The GSEA revealed that the low-risk group exhibited a significant enrichment in immune-associated pathways, while the high-risk group showed significant enrichment in cancer-related pathways. The ESTIMATE and single-sample GSEA algorithms indicated that the low-risk group displayed higher antitumor immunocyte infiltration. TIDE analysis revealed that the low-risk group responded more favorably to immunotherapy. Furthermore, validation experiments revealed that PARP9 is a proto-oncogene associated with the PARP9-JAK2-STAT3 signaling pathway. Conclusion We developed a new NMRS for predicting prognosis and treatment efficacy in glioma. The identified gene, PARP9, is a potential therapeutic target for glioma.

show abstract

miR-10167-3p targets TCF7L1 to inhibit bovine adipocyte differentiation and promote bovine adipocyte proliferation

Hu,

Yang,

Feng

et al. 2024

Genomics

View full text Add to dashboard Cite

TCF3 Induces DNMT1 Expression to Regulate Wnt Signaling Pathway in Glioma

Cited by 4 publications

References 30 publications

Comprehensive analysis of m6A/m5C/m1A-related gene expression, immune infiltration, and sensitivity of antineoplastic drugs in glioma

Comprehensive analysis of m6A/m5C/m1A-related gene expression, immune infiltration, and sensitivity of antineoplastic drugs in glioma

Targeting inhibition of prognosis-related nicotinamide metabolism genes, including poly (ADP-ribose) polymerase 9 (PARP-9) attenuates glioma progression

miR-10167-3p targets TCF7L1 to inhibit bovine adipocyte differentiation and promote bovine adipocyte proliferation

Contact Info

Product

Resources

About